Recently, the Ministry of Industry and Information Technology (MIIT) published the public notice on the number of enterprises to be supported in each province in 2026 under the second round, third batch of the high-quality development program for specialized, refined, distinctive and innovative (SRDI) small and medium-sized enterprises. Usynova Biopharmaceutical Technology (Zhongshan) Co., Ltd. has been successfully recognized as a national-level key SRDI "Little Giant" enterprise.

The national key SRDI "Little Giant" designation is granted through strict review and evaluation by the MIIT, selecting from enterprises already certified as SRDI "Little Giant" enterprises through a process of choosing the best from the best. It represents the benchmark tier of the SRDI system. The title is conferred upon strategic forces whose industrial directions are deeply aligned with national major strategic needs, that support the security and self-reliance of the industrial and supply chains, and that represent the core competitiveness and innovation height of the manufacturing industry. It is one of the highest-level recognitions of an enterprise's innovation capability, professional excellence and industry leadership.

This recognition as a national key SRDI "Little Giant" enterprise is a high-level endorsement of Usynova's innovation strength in biomedical R&D.

Founded in 2020, Usynova is headquartered in Tsuihang New Area, Zhongshan, Guangdong, at the heart of the Guangdong-Hong Kong-Macao Greater Bay Area. It is a biopharmaceutical company driven by clinical data and focused on the R&D of high-barrier innovative drugs. Upholding its core mission of "grounded in science, safeguarding the health of all beings," the company is committed to providing safer and more effective treatment options for patients worldwide. Since its inception, the company has completed nearly RMB 500 million in financing, with a shareholder base bringing together renowned investment institutions including Share Capital, Yingke PE, Yuecai, Zhongshan VC and Zhongqi Capital.

The core management and R&D team brings more than 20 years of complete drug development experience at multinational pharmaceutical companies, covering the full spectrum from target discovery and preclinical research to clinical advancement and commercialization, providing a solid foundation for pipeline development and strategic execution.

Usynova is anchored in the autoimmune disease sector, a golden track valued at over RMB 100 billion, focusing on the development of differentiated "Best-in-Class" and "First-in-Class" small-molecule drugs. Centering on core targets validated both clinically and commercially, including IL-17A, TYK2 and IL-1Ra, the company has built a product matrix with a "near-term, mid-term and long-term" tiered layout:

・UA026 (IL-17A): A globally leading oral small-molecule IL-17A inhibitor that takes on the "undruggable" protein-protein interaction (PPI) target. Its Phase IIa clinical data demonstrate efficacy approaching that of biologics, and it has been innovatively expanded into the dry eye disease market, a blue-ocean opportunity valued at over RMB 10 billion, with First-in-Class potential.

・UA021 (TYK2): A next-generation, highly selective allosteric TYK2 inhibitor that mechanistically avoids the hematological toxicity risk of conventional JAK inhibitors. It achieved a PASI 75 response rate of up to 80.8% in Phase II clinical trials, with efficacy significantly superior to existing oral therapies.

・While continuing to advance its core pipelines, the company maintains a rich early-stage pipeline. Innovative molecules such as UA039 and UA043 are expected to achieve PCC (Preclinical Candidate Compound) status in 2026, continuously injecting new momentum into the mid-to-long-term product pipeline and forming a virtuous cycle of "R&D - output - re-innovation."

Among these, the global rights to the UA022 program have been licensed to AstraZeneca, and the UA026 program has entered into a collaboration with MSD, fully validating the global competitiveness of the company's R&D achievements.

Usynova has built a full-spectrum technology platform covering target validation, molecular design and druggability optimization. Leveraging structural biology, computational chemistry and AI-assisted drug design, the company has achieved precise breakthroughs against traditionally "undruggable" PPI targets and allosteric sites. The company has also established an efficient clinical advancement and management system: the UA026 program took only four months from first patient enrollment to the completion of Phase IIa enrollment, far exceeding the industry average.

Being selected as a national key SRDI "Little Giant" enterprise is both an honor and a responsibility. Taking this as a new starting point, Usynova will continue to increase R&D investment and accelerate the clinical advancement and commercialization of its core pipelines. Leveraging the industrial ecosystem of the Guangdong-Hong Kong-Macao Greater Bay Area and global innovation resources, the company will expand into global markets with an international vision, striving to become an internationally leading benchmark in autoimmune small-molecule drug R&D and commercialization, delivering better and more accessible innovative treatment options to patients worldwide, and contributing to the self-reliance and security of China's biomedical industry chain.